Related Experiment Videos
Raising an isolated low HDL-C level: why, how, and when?
1Center for Preventive Cardiology, Department of Medicine and Epidemiology, University of Maryland Medical Center, Baltimore 21201, USA. mmiller@heart.umaryland.edu
Cleveland Clinic Journal of Medicine
|June 28, 2003
Summary
Treating low high-density lipoprotein cholesterol (HDL-C) requires assessing overall coronary heart disease (CHD) risk. Lifestyle changes and tailored drug therapies can modestly increase HDL-C, potentially reducing CHD event risk.
Area of Science:
- Cardiology
- Metabolic Disorders
- Preventive Medicine
Background:
- Isolated low high-density lipoprotein cholesterol (HDL-C) presents a therapeutic challenge.
- Patient management necessitates a comprehensive assessment of coronary heart disease (CHD) risk.
Purpose of the Study:
- To outline strategies for managing patients with low HDL-C.
- To emphasize the importance of personalized treatment approaches.
Main Methods:
- Review of current lifestyle interventions for HDL-C improvement.
- Evaluation of available pharmacologic therapies targeting HDL-C.
- Risk stratification for coronary heart disease (CHD).
Main Results:
- No single therapy is currently optimal for raising HDL-C.
- Various interventions can achieve modest increases in HDL-C levels.
- These increases correlate with a reduced risk of CHD events.
Conclusions:
- Treatment decisions for low HDL-C should be individualized based on CHD risk.
- Tailored lifestyle and drug therapies are crucial.
- Modest HDL-C elevations can contribute to cardiovascular risk reduction.